8-K: Day One Biopharma Licenses Novel Antibody Drug Conjugate, DAY301, for $55 Million Upfront

Day One Biopharmaceuticals has secured an exclusive worldwide license, excluding Greater China, for a novel antibody-drug conjugate, DAY301, targeting PTK7, paying $55 million upfront and potentially up to $1.15 billion in milestones.

Summary

• Day One Biopharmaceuticals has entered into an exclusive license agreement with MabCare Therapeutics for the development and commercialization of DAY301, a novel antibody-drug conjugate (ADC) targeting protein-tyrosine kinase 7 (PTK7).
• The agreement grants Day One exclusive worldwide rights, excluding Greater China, to develop, manufacture, and commercialize DAY301.
• Day One will pay MabCare an upfront license fee of $55 million.
• MabCare is eligible to receive up to an additional $1.15 billion in development, regulatory, and commercial milestones.
• MabCare will also receive tiered royalty payments ranging from low-to-mid single-digit percentages of net sales of licensed products in the Day One territory.
• The royalty payment obligations expire no earlier than ten years following the first commercial sale of each product in each applicable country.
• The FDA cleared the investigational new drug (IND) application for DAY301 in April 2024.
• Day One expects the first patient to be dosed in a Phase I study in the fourth quarter of 2024 or the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document is positive due to the acquisition of a promising new asset, but there are also significant financial commitments and risks associated with the development of the drug.

Positives

• The acquisition of DAY301 expands Day One's pipeline with a potential first-in-class clinical-stage asset.
• DAY301 targets PTK7, a clinically validated target with limited expression in normal tissues, potentially reducing side effects.
• The linker-payload technology of DAY301 is designed to overcome limitations of previous PTK7-targeted ADCs.
• The FDA has already cleared the IND application for DAY301, accelerating its path to clinical trials.
• Pre-clinical studies have shown anti-tumor activity in a wide range of solid tumors.
• The company has a clear plan to initiate a Phase 1 study in the near future.

Negatives

• The company is paying a substantial upfront fee of $55 million for the license.
• The company is potentially liable for up to $1.15 billion in milestone payments, which could impact future profitability.
• The royalty payments on net sales will reduce the overall revenue from the product.
• The success of DAY301 is not guaranteed, and clinical trials may not yield positive results.
• The company is reliant on the success of a single product to justify the large investment.

Risks

• The development of DAY301 may face regulatory hurdles and delays.
• Clinical trials may not demonstrate the expected efficacy or may reveal unexpected safety issues.
• The company may face competition from other companies developing similar therapies.
• The company may need to raise additional capital to fund the development and commercialization of DAY301.
• The company is reliant on the success of a single product to justify the large investment.

Future Outlook

Day One plans to advance DAY301 into clinical trials, with the first patient expected to be dosed in late 2024 or early 2025. The company aims to develop DAY301 as a potential first-in-class therapy for various solid tumors.

Management Comments

• Jeremy Bender, Ph.D., chief executive officer of Day One, stated that the company's priorities for 2024 include expanding their pipeline by in-licensing clinical-stage assets.
• Dr. Samuel Blackman, co-founder and head of research and development at Day One, believes the linker-payload technology in DAY301 will overcome limitations of earlier PTK7-targeted ADCs.

Industry Context

This announcement reflects a growing trend in the biopharmaceutical industry towards targeted therapies and antibody-drug conjugates. The acquisition of DAY301 positions Day One to compete in the market for cancer treatments, particularly in solid tumors, and aligns with the industry's focus on precision medicine.

Comparison to Industry Standards

• The upfront payment of $55 million is within the range of similar licensing deals for early-stage assets, but the potential $1.15 billion in milestones is substantial and reflects the potential value of the asset.
• The low-to-mid single-digit royalty rates are typical for licensing agreements in the pharmaceutical industry.
• The development of antibody-drug conjugates (ADCs) is a competitive area, with companies like Pfizer and AbbVie also developing PTK7-targeted ADCs, such as cofetuzumab pelidotin, which has shown some clinical activity but also limitations due to toxicity.
• Day One's DAY301 is positioned as a next-generation ADC with improved properties and a better therapeutic index, aiming to overcome the limitations of earlier PTK7-targeted ADCs.

Stakeholder Impact

• Shareholders may view the acquisition of DAY301 positively, as it expands the company's pipeline and potential for future revenue.
• Employees may be impacted by the increased workload associated with the development of a new drug.
• Patients with solid tumors may benefit from the development of a new treatment option.
• Suppliers and partners may see new opportunities for collaboration with Day One.

Next Steps

• Day One will file the License Agreement as an exhibit to their Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2024.
• Day One will initiate a Phase I clinical trial for DAY301, with the first patient expected to be dosed in the fourth quarter of 2024 or the first quarter of 2025.
• The company will continue to develop and advance its existing pipeline programs.

Key Dates

Keywords

DAY301, PTK7, Antibody Drug Conjugate, ADC, MabCare Therapeutics, License Agreement, Oncology, Cancer Therapy, Solid Tumors, Biopharmaceuticals